Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.57 |
| ▸ | MME | P08473 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556650 | 1.00 | TGFBR1 (0.57) | TGFBR1MMECA2CA1FNTA | |
| SCHEMBL783083 | 1.00 | TGFBR1 (0.57) | TGFBR1MMECA2CA1FNTA | |
| SCHEMBL4086458 | 0.92 | TGFBR1 (0.50) | TGFBR1MMECA2CA1 | |
| SCHEMBL29456599 | 0.92 | TGFBR1 (0.50) | TGFBR1MMECA2CA1 | |
| SCHEMBL8542259 | 0.86 | TGFBR1 (0.48) | TGFBR1MMECA2CA1FNTA | |
| SCHEMBL31488806 | 0.86 | TGFBR1 (0.48) | TGFBR1MMECA2CA1FNTA | |
| SCHEMBL4082387 | 0.86 | TGFBR1 (0.48) | TGFBR1MMECA2CA1FNTA | |
| SCHEMBL29051058 | 0.86 | MME (0.50) | TGFBR1MMECA2GNPATCA4 | |
| SCHEMBL29414477 | 0.86 | TGFBR1 (0.44) | TGFBR1MMECA2CA1 | |
| SCHEMBL29051061 | 0.86 | MME (0.50) | TGFBR1MMECA2GNPATCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | claimed |
| CN-117106189-A | Metal organic framework artificial hydrolase and preparation method and application thereof | 华南理工大学 | 2023-11-24 | — | — | CN | claimed |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | claimed |
| EP-2925771-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | Council of Scientific & Industrial Research (IN) | 2015-10-07 | — | — | EP | claimed |
| WO-2014083578-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESERACH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2014-06-05 | — | — | WO | claimed |
| EP-2262521-B1 | OPHTHALMIC COMPOSITIONS COMPRISING A DIPEPTIDE WITH A GLYCINE MOIETY | BAUSCH & LOMB (US) | 2014-02-26 | — | — | EP | claimed |
| EP-2262521-A1 | OPHTHALMIC COMPOSITIONS COMPRISING A DIPEPTIDE | Bausch & Lomb Incorporated (US) | 2010-12-22 | — | — | EP | claimed |
| WO-2009120562-A1 | OPHTHALMIC COMPOSITIONS COMPRISING A DIPEPTIDE | BAUSCH & LOMB INCORPORATED (US) | 2009-10-01 | — | — | WO | claimed |
| US-20090247469-A1 | OPHTHALMIC COMPOSITIONS COMPRISING A DIPEPTIDE | BAUSCH HEALTH AMERICAS, INC. | 2009-10-01 | — | — | US | claimed |
| EP-1282680-A1 | COMPOSITIONS COMPRISING CYCLODEXTRIN | THE PROCTER & GAMBLE COMPANY (US) | 2003-02-12 | — | — | EP | claimed |
| US-6503413-B2 | Polyalkylene polysiloxane, buffering agent, aqueous carrier | THE PROCTER & GAMBLE COMPANY | 2003-01-07 | — | — | US | claimed |
| EP-1255806-A1 | STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-13 | — | — | EP | claimed |
| US-6429220-B1 | COMPRISES AN ISOTHIAZOLONE COMPOUND AND AN AMINOCARBOXYLIC ACID | KURITA WATER INDUSTRIES LTD. (JP) | 2002-08-06 | — | — | US | claimed |
| US-20020011584-A1 | Stable, aqueous compositions for treating surfaces, especially fabrics | THE PROCTOR & GAMBLE COMPANY | 2002-01-31 | — | — | US | claimed |
| US-20020010154-A1 | Compositions comprising cyclodextrin | THE PROCTER & GAMBLE COMPANY | 2002-01-24 | — | — | US | claimed |
| WO-2001088076-A1 | COMPOSITIONS COMPRISING CYCLODEXTRIN | THE PROCTER & GAMBLE COMPANY (US) | 2001-11-22 | — | — | WO | claimed |
| US-6289286-B1 | Surface regeneration of biosensors and characterization of biomolecules associated therewith | BIACORE AB (SE) | 2001-09-11 | — | — | US | claimed |
| WO-2001060961-A1 | STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS | THE PROCTER & GAMBLE COMPANY (US) | 2001-08-23 | — | — | WO | claimed |
| EP-1082607-A1 | SURFACE REGENERATION OF BIOSENSORS | Biacore AB (SE) | 2001-03-14 | — | — | EP | claimed |
| WO-1999063333-A1 | SURFACE REGENERATION OF BIOSENSORS | BIACORE AB (SE) | 1999-12-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | TGFBR1 3218/4885MME 824/4885CA2 4132/4885 |
| US-20020010154-A1 | Compositions comprising cyclodextrin | FFAR4, FRG1, FGB | TGFBR1 1760/4885MME 3638/4885CA2 2473/4885 |
| US-20090247469-A1 | OPHTHALMIC COMPOSITIONS COMPRISING A DIPEPTIDE | GPKOW, GLMN, ARGLU1 | TGFBR1 3647/4885MME 304/4885CA2 1822/4885 |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | CNR2, SRM, CNR1 | TGFBR1 3020/4885MME 1788/4885CA2 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.